Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
Date:9/21/2010

lin resistance.

CCX140 is chemically distinct from all other known antagonists of CCR2 and works by blocking the monocyte/macrophage infiltration that occurs during inflammation and thus is designed to provide selective treatment of the disease without compromising other immune functions.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial.  Phase III clinical trials of Traficet-EN are expected to initiate in the fourth quarter 2010.  In addition, CCX025, also a CCR9 antagonist, has successfully completed a Phase I clinical program. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is private
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Atossa Genetics, Inc. (NASDAQ: ATOS ), The ... , Chief Financial Officer & General Counsel, will present ... May 30, 2013, in New York City ... Company,s presentation is scheduled to begin at 3:30 p.m. EDT ... the webcast, go to www.atossagenetics.com . For ...
(Date:5/17/2013)... May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will release ... 31, 2013, before market on Tuesday, May 28, 2013.  The ... 2013, at 8:00 a.m. EDT (May 28, 2013 at 8:00 ... and provide an update on recent corporate developments. ...
(Date:5/16/2013)... Ill. and MECHELEN, Belgium ... GLPG) and AbbVie (NYSE: ABBV ) announced ... to include Crohn,s disease.  Galapagos will fund and complete ... designed to facilitate rapid progression into Phase 3.  Upon ... AbbVie will pay Galapagos $50 million.  The terms of ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... Dec. 23 BioTrends Research Group, Inc. published ... in the United States," based on ... clinical practice. The report evaluates patient types, ... Hematologists, Oncologists, Nephrologists, Gastroenterologists, OB-GYNs, Rheumatologists, Cardiologists and ...
... , , , PARIS, December ... discovery and development of novel antibiotics,designed to overcome the ... its shareholders have signed a definitive,agreement whereby Novexel shall ... up to $505 million, including contingent payments and the,net ...
Cached Medicine Technology:BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties 2Novexel to be Acquired by AstraZeneca 2Novexel to be Acquired by AstraZeneca 3Novexel to be Acquired by AstraZeneca 4
(Date:5/18/2013)... Park City, Utah (PRWEB) May 18, 2013 ... new information on insurance agents’ role in ... flexible alternatives to traditional employer sponsored health benefits, ... defined contribution and health reimbursement arrangements ... Department of Health and Human Services (HHS) recently ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... York, New York (PRWEB) May 18, 2013 ... to mount in courts throughout the country, Bernstein Liebhard ... metal-on-metal hip replacement patients often suffer tissue damage before ... the study, which according to Science Daily will appear ... metal-on-metal hip replacement recipients underwent MRI screens of their ...
(Date:5/18/2013)... 2013 The “Sleep Apnea Diagnostic & ... Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] ... analyzes and studies the major market drivers, restraints, and ... the World. , Browse , ... Figures , 318 pagesand in-depth TOC ...
(Date:5/18/2013)... 18, 2013 The Ayurvedic practitioner program ... institution in the West. Program is available in Mexico ... is a healing modality practiced for over 5,000 years. ... considered that health begins when an individual lives in ... their individual needs. Ayurveda aims to heal an individual ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2
... grant from the Office of the National Coordinator ... Hospital Boston and Harvard Medical School have developed ... flexible health information technology (IT) environment and promote ... platform and interface are being made publicly available ...
... (BA) is an inflammatory obliterative cholangiopathy with unknown ... technology, emerged as an indispensable research tool for ... the mechanism underlying BA, and allows the simultaneous ... experiment. Some studies have been performed to investigate ...
... , MONDAY, March 7 (HealthDay News) -- Children prefer cereals ... package, regardless of how they taste, researchers say. "This ... are going to be more likely to enjoy their cereal ... said Keri Gans, a spokeswoman for the American Dietetic Association ...
... 8, 2011 As the debate about healthcare in the ... issue of The American Journal of Medicine strive ... dialog. The issue leads off with the editorial, "The ... Dr. Joseph Alpert, Professor of Medicine, Arizona College of Medicine, ...
... , MONDAY, March 7 (HealthDay News) --Taste cells apparently ... formerly thought to exist only in the pancreas and ... to the development of new interventions designed to help ... sweetness of nutritive sugars is one of the most ...
... LA JOLLA, CA, AND JUPITER, FL March 7, ... until March 7, 2011, 3 PM, Eastern time Working ... to find potential medicines and other biologically useful molecules, ... of Technology (MIT) have discovered an extremely potent class ...
Cached Medicine News:Health News:Boston researchers create 'SMArt' platform architecture, launch $5,000 health app competition 2Health News:Cartoon Branding Affects Kids' Cereal Choice, Regardless of Taste 2Health News:Cartoon Branding Affects Kids' Cereal Choice, Regardless of Taste 3Health News:The sorry state of health of US medicine 2Health News:The sorry state of health of US medicine 3Health News:The sorry state of health of US medicine 4Health News:New Sweetness Detectors Found in Human Taste Cells 2Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 2Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 3Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 4
... research model of the Bowman Perfusion Monitor ... continuously in real-time. This precision instrument activates ... which is connected by an umbilical cord ... digital form and send the data to ...
Housed in a small lightweight, flame retardant plastic cases, meters are equipped with a convenient multiposition handle/stand. Measure microcirculation in 1 cubic mm of tissue for real-time assessme...
... featured laser doppler system for continuous ... multiple tissue sites. This latest generation ... Processing (DSP) and laser Doppler flowmetry ... to use, multi-channel monitor, setting new ...
Transcranial vascular DWL doppler....
Medicine Products: